Comprehensive Safety Review of Semaglutide Across 16 Clinical Trials and Over 11,000 Patients

What the researchers found

Across 16 Phase IIIa trials (n=11,159; subcutaneous semaglutide n=3,150; oral semaglutide n=4,116):

- GI disorders: 41.9% (subcutaneous) / 39.1% (oral) vs 22.0% / 24.8% comparators — most common during dose escalation, decreasing with continued therapy

- No increased risk vs comparators for: kidney disorders, acute pancreatitis, malignant neoplasms, hypoglycemia, heart failure, or other cardiovascular events

- Cholelithiasis (gallstones): incidence higher with both formulations vs placebo

- Diabetic retinopathy: higher with subcutaneous semaglutide vs placebo in SUSTAIN 6

- Small pulse rate increases with both formulations; no increased arrhythmias

- Fatal adverse events: similar rates between semaglutide and comparators

- CVOTs: reduced MACE with subcutaneous semaglutide; non-inferiority met with oral

Why it matters

As semaglutide is now prescribed to millions of people for both diabetes and obesity, this comprehensive safety analysis from the largest clinical trial programmes provides essential evidence for informed prescribing decisions. The reassuring safety profile across multiple organ systems supports its widespread use while identifying specific areas for monitoring (gallstones, retinopathy).

How the study worked

Pooled analysis of adverse event data from 16 randomized, placebo- or active-controlled Phase IIIa trials from the SUSTAIN programme (subcutaneous semaglutide) and PIONEER programme (oral semaglutide). Separate analyses were conducted for cardiovascular outcomes trials (CVOTs; n=6,480). Safety endpoints included GI disorders, kidney events, pancreatitis, neoplasms, hypoglycemia, retinopathy, cardiovascular events, and mortality.

What this study cannot tell us

The analysis covers Phase IIIa trial data, which may not capture rare events or long-term safety beyond trial durations. Trial populations were selected using inclusion/exclusion criteria and may not represent all real-world patients. The higher retinopathy signal in SUSTAIN 6 may be related to rapid HbA1c improvement rather than a direct drug effect. Post-marketing surveillance has since provided additional safety data not captured here.

How to read the evidence

This is a comprehensive pooled analysis of 16 randomized Phase IIIa clinical trials — among the highest levels of safety evidence available for a medication. The large sample size and diverse comparator arms provide robust safety conclusions.

When this study was published

Published in 2023, this analysis covers the foundational safety data from all Phase III semaglutide trials. Post-marketing real-world safety data has since accumulated further.

The bigger picture

This pooled analysis represents the definitive Phase III safety evaluation of semaglutide before its massive expansion into the obesity market. The data has been instrumental in informing prescribing guidelines and patient counseling. The identified risk signals — gallstones and early diabetic retinopathy worsening — have become key discussion points in clinical practice.

Questions still open

• Do the higher-dose obesity indications (2.4 mg) carry a different safety profile than the diabetes doses analyzed here?
• Is the gallstone risk clinically significant enough to warrant screening before starting semaglutide?
• Does the early diabetic retinopathy worsening stabilize with continued therapy or require monitoring changes?

Common questions

Read the original research

Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.

Diabetes, obesity & metabolism, 25(5), 1385-1397

Citation

Aroda, Vanita R; Erhan, Umut; Jelnes, Peter; Meier, Juris J; Abildlund, Morten Tind; Pratley, Richard; Vilsbøll, Tina; Husain, Mansoor. (2023). Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.. Diabetes, obesity & metabolism, 25(5), 1385-1397. https://doi.org/10.1111/dom.14990